Processa Pharmaceuticals

Processa Pharmaceuticals is a clinical stage biopharmaceutical company based in Hanover, Maryland, focused on developing drugs to address unmet medical needs in the United States. The company's lead product candidate, PCS499, is an oral tablet currently in Phase II trials aimed at treating necrobiosis lipoidica, a chronic skin condition. Additionally, Processa is advancing PCS12852, a selective 5-HT4 receptor agonist in Phase II trials for post-operative ileus, and PCS6422, a selective and irreversible inhibitor in Phase I trials targeting metastatic colorectal and breast cancer. The company also holds a licensing agreement with Akashi Therapeutics to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. Established in 2015, Processa Pharmaceuticals emphasizes a regulatory science approach to enhance the effectiveness and safety of its drug development initiatives.